ストックスクリーナーアプリを入手
2.1808
1.43%
0.0308
アフターアワーズ：
2.18
-0.0008
-0.04%
前日終値:
$2.15
開ける：
$2.185
24時間の取引高:
6,817
Relative Volume:
0.82
時価総額：
$14.92M
収益：
$105.38M
当期純損益:
$17.78M
株価収益率:
0.8168
EPS:
2.67
ネットキャッシュフロー:
$-50.48M
1週間 パフォーマンス:
-2.64%
1か月 パフォーマンス:
+3.00%
6か月 パフォーマンス:
-19.23%
1年 パフォーマンス:
-22.67%
1日の値動き範囲:
$2.11
$2.198
1週間の範囲:
$2.10
$2.245
52週間の値動き範囲:
$1.46
$4.10
Mei Pharma Inc Stock (MEIP) Company Profile
MEIP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.1808 | 14.92M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-23 | ダウングレード | Laidlaw | Buy → Hold |
| 2022-03-25 | ダウングレード | Jefferies | Buy → Hold |
| 2022-03-25 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | 開始されました | Jefferies | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-29 | 開始されました | SunTrust | Buy |
| 2018-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2018-07-27 | アップグレード | Stifel | Hold → Buy |
| 2018-07-13 | 開始されました | SunTrust | Buy |
| 2016-04-18 | 繰り返されました | Wedbush | Neutral |
| 2015-03-23 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-18 | 繰り返されました | ROTH Capital | Buy |
| 2014-10-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Brean Capital | Buy |
| 2013-10-22 | 繰り返されました | Stifel | Buy |
| 2013-04-15 | 開始されました | Stifel | Buy |
すべてを表示
Mei Pharma Inc (MEIP) 最新ニュース
Northern Trust Corp Increases Stock Holdings in MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid - The Globe and Mail
MEI Pharma Reports Significant Revenue Decline - TipRanks
MEIP Explores Strategic Options to Enhance Shareholder Value | M - GuruFocus
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position - GuruFocus
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
This More Than 5%-Yielding Dividend Stock Looks Like a Can't-Miss Buy for Income and Upside Potential - The Globe and Mail
A new MEI study highlights the importance of micro-entrepreneurs in supplying drinking water to poorer neighbourhoods in Ivory Coast - GlobeNewswire Inc.
10 Best NASDAQ Stocks to Buy According to Billionaires - Insider Monkey
Inside Buffett’s $334B Cash Pile: Get Ready for Berkshire Hathaway Earnings - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Sharp Co. (OTCMKTS:SHCAY) Short Interest Down 25.8% in March - The AM Reporter
11 Best Internet Retail Stocks to Buy According to Analysts - Insider Monkey
Billionaire David Tepper’s Top 10 Stock Picks - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
Will the Stock Market Crash As President Trump's Tariffs Take Effect? History Offers a Clue. - The Globe and Mail
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Cautious Investors Should Wait for THIS Entry Point Before Buying Nvidia Stock - The Globe and Mail
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
Mei Pharma Inc (MEIP) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):